Replies to post #203608 on Biotech Values

[DewDiligence]

EARS -31%/AH on second phase-3 failure in tinnitus:

https://finance.yahoo.com/news/auris-medical-provides-business-201545128.html

It’s surprising that enough people expected success for the stock to be down so much in AH trading. The second phase-3 trial was not much different from the first phase-3 that failed, and neither of them was based on successful phasse-2 data (#msg-124612678).